The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | ALPINE results: zanubrutinib vs. ibrutinib in CLL
The ALPINE study (NCT03734016) investigated zanubrutinib vs. ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL). Here, Constantine Tam, MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the results thus far from the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
